Back to Search Start Over

Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity

Authors :
Hajer Fritah
Michele Graciotti
Cheryl Lai-Lai Chiang
Anne-Laure Huguenin- Bergenat
Rémy Petremand
Ritaparna Ahmed
Philippe Guillaume
Julien Schmidt
Brian J. Stevenson
David Gfeller
Alexandre Harari
Lana E. Kandalaft
Source :
iScience, Vol 26, Iss 4, Pp 106288- (2023)
Publication Year :
2023
Publisher :
Elsevier, 2023.

Abstract

Summary: Antigen selection and prioritization represent crucial determinants of vaccines’ efficacy. Here, we compare two personalized dendritic cell-based vaccination strategies using whole-tumor lysate or neoantigens. Data in mouse and in cancer patients demonstrate that peptide vaccines using neoantigens predicted on the sole basis of in silico peptide-major histocompatibility complex (MHC) binding affinity underperform relative to whole-tumor-lysate vaccines. In contrast, effective in vitro peptide-MHC binding affinity and peptide immunogenicity significantly improve the prioritization of tumor-rejecting neoepitopes and result in more efficacious vaccines.

Details

Language :
English
ISSN :
25890042
Volume :
26
Issue :
4
Database :
Directory of Open Access Journals
Journal :
iScience
Publication Type :
Academic Journal
Accession number :
edsdoj.9001342654b947c8becf2723dc803e5f
Document Type :
article
Full Text :
https://doi.org/10.1016/j.isci.2023.106288